An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
- 31 March 2012
- journal article
- review article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 11 (1), 1-13
- https://doi.org/10.1016/j.clcc.2011.05.005
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME StudyJournal of Clinical Oncology, 2010
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJama-Journal Of The American Medical Association, 2010
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisThe Lancet Oncology, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Biology of Colorectal CancerThe Cancer Journal, 2010
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2Journal of Clinical Oncology, 2010
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerThe New England Journal of Medicine, 2009
- Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III StudyJournal of Clinical Oncology, 2008
- OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal CancerJournal of Clinical Oncology, 2005